- 2019
- Press releases - 03.12.2019
Metastasis: When Cancer Cells Hitch a Ride Through the Bloodstream
Circulating tumor cells use the blood and lymphatic networks to disseminate within the body, forming metastases distant from the primary tumor. Inserm researcher Jacky Goetz and his Tumor Biomechanics team at the Molecular ImmunoRheumatology laboratory (Inserm/Université de Strasbourg) have helped to show that the flow properties of these biological fluids have a huge influence on the risk of developing metastases.
- Press releases - 02.12.2019
Restoring Sight: the Artificial Retina Shows Growing Promise
Restoring sight to patients with age-related macular degeneration (AMD) or retinitis pigmentosa has become an increasingly likely prospect over recent years, with many researchers working to develop an artificial retina.
- Press releases - 26.11.2019
Influenza : the Reasons for Low Vaccine Coverage Among Pregnant Women
A study reveals that seasonal influenza vaccine coverage remains particularly low among pregnant women in France. Despite risks of severe complications, expectant mothers are often not offered the vaccine during their prenatal monitoring or, if they are, a large majority declines it.
- Press releases - 25.11.2019
20 YEARS OF INSERM PRIZES: Honoring science for health
This year marks the 20th annual Inserm Prize ceremony, to take place on Tuesday December 10 at Collège de France in celebration of six researchers and engineers whose achievements have helped raise the level of scientific excellence at the Institute, in the service of health for all.
- Press releases - 20.11.2019
Reprise de la campagne de vaccination contre la grippe
Comment surveille-t-on la diffusion des symptômes grippaux en France métropolitaine?
- What's on? - 20.11.2019
Reprise de la campagne de vaccination contre la grippe
D’après la Fédération des pharmaciens d’officine (FSPF), plus d’un million de personnes en France s’étaient déjà faites vaccinées contre la grippe au 1er novembre 2019, deux semaines après le lancement de la campagne annuelle. Avec le réseau Sentinelles et le projet Grippenet, l’Inserm participe activement à la surveillance des apparitions de symptômes grippaux sur […]
- Press releases - 20.11.2019
Towards a Drug to Combat a Severe Intestinal Disease in Children, Immunocompromised Patients
Researchers have recently discovered a new candidate drug to control cryptosporidiosis, a severe intestinal disease in children, immunocompromised patients, and young ruminants. Beyond this disease, their research represents an opportunity to discover new therapeutic avenues for related infections, such as toxoplasmosis and malaria.
- Press releases - 15.11.2019
Operation Cortex: an Escape Game by Inserm
Inserm’s first ever escape game, Operation Cortex, an immersive experience to raise awareness of health research, opens its doors to the general public on November 15. This new public interaction format fulfils the institute’s desire to promote scientific culture and enable visitors to discover its laboratories.
- Press releases - 13.11.2019
Type 1 diabetes : a research update from Inserm
From the discovery of insulin in 1921 to the first ever pancreas transplants in the late 1960s, the recent history of type 1 diabetes research has brought scientific and medical advances which have transformed patient prognosis and quality of life. Here at Inserm, eleven teams distributed among nine units contribute their own endeavors. Their work primarily involves the characterization of pancreatic cells and improving knowledge of the disease (risk factors, genetic susceptibility, pathophysiological mechanisms) and its complications. One of these teams, based in Lille, is exploring islet transplantation, a promising technique discussed in a new publication in Diabetes Care[1] and in an update in The Lancet[2]. Other very interesting avenues currently being explored include immunotherapy and the development of artificial pancreases.
- Press releases - 05.11.2019
A Vaccine to Overcome Immunotherapy Resistance
Researchers have shown that a commercially-available vaccine can overcome resistance to immunotherapy. Their study, published in Science Translational Medicine, shows that not only can gastroenteritis vaccines induce the immunogenic death of cancer cells in vitro, but also that combining them with immunotherapy triggers a potent anti-tumor immune response in vivo – where immunotherapy alone had failed.